The Recall Desk

Severity 4 of 5

Severe recalls

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

What “severe” means here

Severity 4 (Severe) recalls have a real, documented risk of significant injury, hospitalization, or property damage even if no deaths have been reported. The agency classification is FDA Class II with hospitalization reports, USDA Class I, or a structural vehicle defect. These need attention quickly — not five-alarm urgency but not something to put off. Examples include allergen mislabeling on common allergens for products eaten by children, drug potency out of specification by a margin that could cause measurable harm, and vehicle defects affecting braking or steering.

The full rubric is on the methodology page. Severity is computed deterministically from the agency’s own classification plus the source text — no editorial vibes.

23051–23075 of 32176

  • SevereFDA (Drugs)·D-653-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol (Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Estradiol (Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-683-2015·2015-04-29

    Fluorexon API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Fluorexon active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Fluorexon active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-953-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vidarbine Monophosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vidarbine Monophosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Vidarbine Monophosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-930-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tiopronin Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tiopronin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tiopronin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-906-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfanilamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfanilamide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Sulfanilamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-718-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxocobalamin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-556-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcitriol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling calcitriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Calcitriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-606-2015·2015-04-29

    Cyclophosphamide Monohydrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Cyclophosphamide Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Cyclophosphamide Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-764-2015·2015-04-29

    Linezolid API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Linezolid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Linezolid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-883-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rocuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rocuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Rocuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-919-2015·2015-04-29

    Attix Pharmaceuticals Recalls Terbinafine Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Terbinafine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Terbinafine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-671-2015·2015-04-29

    Famciclovir Recalled Due to Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling famciclovir active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Famciclovir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-799-2015·2015-04-29

    Attix Pharmaceuticals Recalls Minocycline HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Minocycline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Minocycline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-957-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zinc Pyrithione Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Zinc Pyrithione active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Zinc Pyrithione active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-758-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levofloxacin Hemihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levofloxacin Hemihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levofloxacin Hemihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-830-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pancuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pancuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pancuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-761-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levothyroxine Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levothyroxine Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levothyroxine Sodium (T4) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-886-2015·2015-04-29

    Attix Pharmaceuticals Recalls Roxithromycin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Roxithromycin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Roxithromycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-841-2015·2015-04-29

    Attix Pharmaceuticals Recalls Phentolamine Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Phentolamine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Phentolamine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-954-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vincristine Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vincristine Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Vincristine Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-562-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carboplatin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carboplatin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Carboplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-727-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ibuprofen Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling ibuprofen active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ibuprofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-859-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pregabalin Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling pregabalin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pregabalin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-643-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxycycline Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxycycline Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxycycline Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-956-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zidovudine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Zidovudine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Zidovudine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide